BFRI - Biofrontera Inc.
IEX Last Trade
1.11
0.010 0.901%
Share volume: 874
Last Updated: Fri 27 Dec 2024 08:30:09 PM CET
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
0.90%
PREVIOUS CLOSE
CHG
CHG%
$1.10
0.01
0.91%
Fundamental analysis
4%
Profitability
0%
Dept financing
0%
Liquidity
0%
Performance
10%
Performance
5 Days
5.94%
1 Month
8.08%
3 Months
-16.41%
6 Months
18.89%
1 Year
-62.06%
2 Year
-93.71%
Key data
Stock price
$1.11
DAY RANGE
$1.08 - $1.10
52 WEEK RANGE
$0.72 - $3.90
52 WEEK CHANGE
-$61.37
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/07/2024
Company detail
CEO: Erica L. Monaco
Region: US
Website: biofrontera.us.com
Employees: 70
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: biofrontera.us.com
Employees: 70
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Biofrontera Inc. engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company offers Ameluz, which is a prescription drug approved for use in combination with the company's licensor's medical device. The RhodoLED lamp series for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp.
Recent news